CN Patent

CN102036963A — 作为蛋白酪氨酸激酶抑制剂的喹啉类和喹喔啉类衍生物

Assigned to Novartis AG · Expires 2011-04-27 · 15y expired

What this patent protects

本发明涉及游离形式或其药学上可接受的盐、溶剂合物、酯、N-氧化物形式的式(I)化合物，其中取代基如说明书中所定义；其制备方法；涉及含有所述化合物的药物，特别是用于治疗一种或多种蛋白酪氨酸激酶介导的疾病的药物。

USPTO Abstract

本发明涉及游离形式或其药学上可接受的盐、溶剂合物、酯、N-氧化物形式的式(I)化合物，其中取代基如说明书中所定义；其制备方法；涉及含有所述化合物的药物，特别是用于治疗一种或多种蛋白酪氨酸激酶介导的疾病的药物。

Drugs covered by this patent

Patent Metadata

Patent number
CN102036963A
Jurisdiction
CN
Classification
—
Expires
2011-04-27
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.